Results 101 to 110 of about 119,873 (307)
Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access
Clinical Pharmacology &Therapeutics, EarlyView.Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian +5 more
wiley +1 more source
Editorial: Artificial intelligence for data discovery and reuse in endocrinology and metabolism
, 2023 As biomedical research has embraced the era of big data, massive amounts of complex multi-omic data are being generated. While there is huge potential in using the rich body of data to make new discoveries, many challenges exist in the dissemination ...
Huajin Wang +5 more
core +1 more source
International Journal of Eating Disorders, EarlyView.ABSTRACT Objective To evaluate the feasibility of a randomized pilot trial of group‐based cognitive behavioral therapy (CBT) for binge eating disorder (BED) in individuals with type 2 diabetes, and to estimate exploratory clinical outcomes to inform the design of a future efficacy trial. Method Thirty‐four participants with type 2 diabetes and BED were
Pernille Fiil Nybo +4 more
wiley +1 more source
The Burden of Multiple Metabolic Diseases and Their Impact on Cardiovascular and Kidney Complications in Type 2 Diabetes: A 10-Year Real-World Study [PDF]
Man-Rong Xu,1 Meng-Han Li,1 Ya-Wen Zhang,1 Jun-Xi Lu,1 Lian-Xi Li,1 Yu-Ren Zhang2 1Department of Endocrinology and Metabolism, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Clinical Center for ...
Li LX +5 more
core
Eye &ENT Research, EarlyView.ABSTRACT Artificial intelligence (AI) is reshaping ophthalmology from task‐specific image analysis toward multimodal, longitudinal, and clinically integrated decision support. This narrative review summarizes the methodological evolution of ophthalmic AI, including traditional machine learning, task‐specific deep learning, self‐supervised learning ...
Yuxin Liu, Hanruo Liu
wiley +1 more source
Cardiovascular Diabetology, 2019 Background Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reported to improve glycaemic control in ...
Chenguang Li +12 more
doaj +1 more source
Metabolic Fingerprint of Chronic Obstructive Lung Diseases: A New Diagnostic Perspective
, 2019 Chronic obstructive lung disease (COLD) is a group of airway diseases, previously known as emphysema and chronic bronchitis. The heterogeneity of COLD does not allow early diagnosis and leads to increased morbidity and mortality. The increasing number of
Gerasimos Tsilimidos +6 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger +15 more
wiley +1 more source
European Thyroid JournalApalutamide, a selective androgen receptor antagonist, is a new treatment for prostate cancer. Among the side effects observed during apalutamide treatment, an increased risk of hypothyroidism has been reported, particularly in patients previously ...
Florie Quattrochi +2 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao +27 more
wiley +1 more source